In early-stage HCC patients (TNM stages I-II), low-MACC1 expression patients revealed a 5-year survival rate of 57%, whereas the survival rate decreased to 14% in the high MACC1 group (P<0.001, Figure 4C). Here, MACC1 is linked to hepatocellular carcinoma.